New scan could sharpen bladder cancer staging
NCT ID NCT04018053
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study tested whether a new radioactive tracer called 18F-fluciclovine, used with a PET/CT scan, can better determine the extent of muscle invasive bladder cancer before surgery. Sixteen participants with bladder cancer received the tracer and scan before their planned bladder removal. The goal was to see if the scan could more accurately detect cancer spread compared to standard CT or MRI scans.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
18F-fluciclovine (a radioactive tracer used in PET scans)
What this could lead to
If successful, this could lead to more accurate staging of bladder cancer, helping doctors choose the best treatment and avoid unnecessary surgery.
What could go wrong
This is a very early, small pilot study with only 16 participants. The tracer may not prove more accurate than current methods, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States